The transcription factor Forkhead box O3 (Foxo3) has a critical role in suppressing the expansion of antigen-specific effector T-cell populations; hence, Foxo3 is a potential target for enhancing the antitumor immunity of cancer vaccines. In this report, we evaluated the potential of RNA interference (RNAi)-mediated silencing of Foxo3 in antigen-presenting cells as an adjuvant for HER2/neu DNA cancer vaccines. Bicistronic plasmids expressing the N-terminal extracellular domain of human HER-2/neu and the Foxo3 short hairpin RNA (hN'-neu-Foxo3 shRNA) or the scrambled control (hN'-neu-scramble shRNA) were subcutaneously injected into mice by gene gun administration to elicit antitumor immunity against p185neu-overexpressing MBT-2 bladder tumor cells. We found that mice treated with hN'-neu-Foxo3 shRNA showed greater reductions in tumor growth and longer survival times than mice treated with hN'-neu-scramble shRNA, indicating that the silencing of Foxo3 enhanced the antitumor efficacy of the HER-2/neu cancer vaccine. Cytotoxicity analyses further revealed that the Foxo3 shRNA-enhanced antitumor effect was associated with significant increases in the number of functional CD8 + T cells and in the levels of cytotoxic T lymphocytes activity. Interleukin-6 was induced by hN'-neu-Foxo3 shRNA treatment but did not have a critical role in the antitumor effect of the hN'-neu-Foxo3 shRNA vaccine. Moreover, in vivo lymphocyte depletion analyses confirmed that the antitumor efficacy of the hN'-neu-Foxo3 shRNA vaccine depended on functional CD8 + T cells. Finally, Foxo3 suppression was shown to markedly improve the effect of the HER-2/neu DNA vaccine in limiting the growth and lung metastases of MBT-2 cells. Overall, these results support RNAi-mediated silencing of Foxo3 as an effective strategy to enhance the therapeutic antitumor effect of HER-2/neu DNA vaccines against p185neu-positive tumors.
INTRODUCTION
DNA vaccines offer a new and powerful approach for generating antigen-specific cancer vaccines and immunotherapies. 1 Administration of DNA vaccines via gene gun can be used to deliver the genes of interest directly into professional antigen-presenting cells (APCs), such as dendritic cells (DCs), in the dermal and epidermal layers of the skin. 2 These bone marrow-derived APCs prime antigen-specific major histocompatibility complex-restricted T cells in draining lymphoid organs. 3 Nevertheless, the potency of these vaccines is often limited by signaling pathways that negatively regulate the adaptive immune response. Thus, silencing of these immunosuppressive signals represents a potential strategy to enhance DNA vaccine potency.
With respect to cancer immunotherapy, RNA interference (RNAi) has been exploited as a complement to DNA vaccines because RNAi can silence the expression of genes encoding immunosuppressive factors. 4 To this end, the antitumor efficacy of DNA vaccines can be enhanced when administered via gene gun in conjunction with short hairpin RNAs (shRNAs) that target key proapoptotic proteins including Bax, Bak or Fas ligand; [5] [6] [7] immunosuppressive cytokines such as interleukin (IL)-10; 8 or immunoregulatory proteins such as indoleamine 2,3-dioxygenase. 9 Consequently, these lines of evidence support the notion that gene gun administration represents an efficient method for the in vivo delivery of shRNAs into professional APCs to modulate the antitumor immunity elicited by DNA vaccines.
The Forkhead box O3 (Foxo3) family of transcription factors has been implicated in several vital cellular processes, including cell cycle progression, survival and DNA repair. 10, 11 So far, four Foxo members, namely, Foxo1, Foxo3, Foxo4 and Foxo6, have been found in mammals. 12 Recently, accumulating evidence has revealed the importance of the Foxo family in the coordination of immune responses. In particular, activation of Foxo3 in T cells leads to growth suppression and apoptosis, indicating the vital role of Foxo3 in maintaining T-cell homeostasis and in restraining T-cell activity. [13] [14] [15] Furthermore, Fallarino et al. 16 reported that the activation of Foxo3a is essential for the suppression of DC function following treatment with cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-immunoglobulin, a soluble form of CTLA-4. Additionally, Dejean et al. 17 demonstrated that deficiency in Foxo3 lead to an expansion of the antigen-specific effector T-cell population following viral infection. These results underpinned the fundamental effect of Foxo3 on the DC-mediated modulation of T-cell responses and led us to propose that Foxo3 represents a potential target to be suppressed by RNAi in DCs to sustain the survival of activated antigen-specific T cells and to enhance DNA vaccine potency.
In this report, we present the first evidence that validates that RNAimediated suppression of Foxo3 in APCs represents an effective strategy to enhance the antitumor efficacy of HER-2/neu DNA vaccines. We choose HER-2/neu as the model antigen because it has been well established that the HER-2/neu protein is overexpressed in several types of human cancers and that its overexpression is associated with cancer progression and poor prognosis. 18 Effective HER-2/neu DNA vaccines may potentially be used for the therapeutic control of HER-2/neu-overexpressing tumor growth in several preclinical models. [19] [20] [21] [22] [23] We demonstrated that the hN'-neu-Foxo3 shRNA vaccine enhanced the therapeutic antitumor effect of the HER-2/neu DNA vaccine and also significantly increased the level of HER-2/neuspecific CD8 + T cells. Accordingly, we propose that the suppression of Foxo3 in APCs has implications for the design of future clinical trials aimed to evaluate novel DNA cancer vaccines.
RESULTS

Construction and characterization of a DNA vaccine combining both the HER-2/neu antigen and Foxo3 shRNA
To test the effect of Foxo3 suppression on the antitumor potency of the HER-2/neu DNA vaccine, we constructed two bicistronic plasmids expressing both the N-terminal extracellular domain of human ErbB2 (HER-2/neu) and Foxo3 shRNA or its scrambled shRNA control (denoted as 'hN'-neu-Foxo3 shRNA' and 'hN'-neu-scramble shRNA,' respectively). The construction strategy for these two HER-2/neu DNA vaccines is diagramed in Figure 1 . To evaluate the expression of the N-terminal extracellular domain of HER-2/neu and the efficiency of Foxo3 suppression by these DNA vaccines, COS-7 cells were co-transfected with either of these two DNA vaccines together with an additional plasmid-expressing murine Foxo3; subsequently, the levels of HER-2/neu and Foxo3 were determined by western blot analysis. As shown in Figure 2a , cells transfected with the hN'-neuFoxo3 shRNA or the hN'-neu-scramble shRNA DNA vaccines showed similar HER-2/neu expression. In contrast, the level of Foxo3 was markedly reduced in cells transfected with the hN'-neu-Foxo3 shRNA compared with cells transfected with the hN'-neu-scramble shRNA. To validate HER-2/neu expression and Foxo3 silencing in cells exposed to these DNA vaccines in vivo, we co-administrated the shRNA or hN'-neu DNA vaccines with a plasmid-expressing green fluorescent protein (GFP) to skin DCs. At 72 h after DNA plasmid administration, CD11c + GFP + double-positive cells were isolated from the inguinal lymph nodes, which served as the shRNA or DNA vaccine-expressing CD11c + cells for subsequent analyses of the mRNA levels of HER-2/ neu and Foxo3 using quantitative real-time reverse transcription PCR. Consistent with our previous findings in COS-7 cells, similar levels of HER-2/neu mRNA were observed in CD11c + DCs isolated from mice vaccinated with either the hN'-neu-Foxo3 shRNA or the hN'-neuscramble shRNA. Importantly, the levels of Foxo3 mRNA were markedly reduced in CD11c + DCs from mice treated with the hN'-neu-FOXO3 shRNA compared with the levels in CD11c + DCs from mice treated with the hN'-neu-scramble shRNA (Figure 2b ). Overall, these results showed that the N-terminal extracellular domain of HER-2/neu antigen is expressed by these constructed dual-function DNA vaccines and also validated the in vitro and in vivo specific suppression of Foxo3 using the Foxo3 shRNA that we designed.
Silencing of Foxo3 facilitated DC-induced Ag-specific T-cell differentiation
Previous studies have demonstrated that Foxo3-deficient DCs can enhance T-cell responses. 16, 17 In addition, the induction of antigenspecific T-cell differentiation or activation may be the critical function of DCs stimulated by DNA vaccines. 24 Thus, we proceeded to examine whether Foxo3 shRNA-transfected DCs can affect antigen-specific T-cell differentiation. To this end, CD8 + OT-I cells were co-cultured with 10 mg ml -1 OVA-257À264 (OVAP 1 )-pulsed Foxo3 shRNA, hN'-neu-Foxo3 shRNA or scrambled shRNA control-transfected bone marrow-derived DCs (BMDCs) for 18 h. Subsequently, the level of differentiation of the CD8 + OT-I T cells into functionally mature IFN-g-producing Ovabumin (OVA)-specific CD8 + T cells than the scrambled shRNA-transfected DCs did (Figures 3b and c) , indicating that Foxo3 suppression in DCs enhanced the potency of DCs to induce Ag-specific T-cell differentiation/activation in vitro.
Silencing of Foxo3 improves the survival of DCs
Foxo3 activation has been shown to induce apoptosis, whereas Foxo3 deficiency impairs apoptosis. [13] [14] [15] Accordingly, we next examined whether silencing Foxo3 rendered DCs resistant to T cell-induced apoptosis. To test this, we incubated OVA peptide-loaded Foxo3 shRNA-transfected BMDCs or scrambled shRNA-transfected BMDCs from C57/B6 mice with OVA-specific CD8 + T cells from OT-1 mice for 24 h, and the number of apoptotic DCs was then determined. We found that 20-40% of OVA peptide-loaded, scrambled shRNA-transfected DCs was apoptotic, whereas DCs transfected with Foxo3 shRNA were more resistant to CD8 + T-cell-induced apoptosis at 10:1 and 1:1 DC:T-cell ratios (Figure 4a ). To further test the effect of Foxo3 silencing on the survival of DCs in vivo, we primed mice with the hN'-neu DNA vaccine to generate HER-2/neu-specific CD8 + T cells to test the anti-apoptotic ability of hN'-neu-Foxo3 shRNA-transfected DCs. One week later, we co-administrated the shRNA or the DNA vaccine construct with a plasmid-expressing GFP (EGFP-N1), which served as a fluorescent marker to identify DNA-transfected DCs in the lymph nodes. These CD11c + GFP + double-positive cells were then subjected to flow cytometry analyses to determine the cell numbers and the level of apoptotic death revealed by Annexin V staining. As shown in Figures 4b and c, 3 days after the last immunization, there was no significant difference between the percentage of CD11c + GFP + cells in mice given EGFP-N1 mixed with the scramble shRNA and in mice given the Foxo3 shRNA. However, we detected a higher percentage of CD11c + GFP + cells in mice given the hN'-neu-Foxo3 shRNA than in mice given the hN'-neu-scramble shRNA control. Consistently, a lower level of apoptotic CD11c + GFP + cells was observed in mice given the hN'-neu-Foxo3 shRNA than in mice given the hN'-neu-scramble shRNA (Figure 4d ). Taken together, these results clearly indicated that Foxo3 suppression by the hN'-neu-Foxo3 shRNA DNA vaccine prolonged the survival of DCs, possibly because of the resistance of DCs to apoptosis induced by CD8 + T cells.
Foxo3 shRNA enhances the antitumor efficacy of the HER-2/neu DNA vaccine Given the inhibitory effect of Foxo3 on the function and survival of DCs, we next examined whether silencing Foxo3 would enhance the antitumor potency of the HER-2/neu DNA vaccine. We implanted C3H/HeN mice with p185neu-overexpressing MBT-2 bladder tumor cells and then vaccinated the mice subcutaneously with shRNAs or the two bicistronic HER-2/neu DNA vaccines. As shown in Figures 5a and b, neither the Foxo3 shRNA nor scrambled shRNA alone could control tumor growth, and all mice in these two groups had to be killed because of the size of their tumors or their condition; it is expected that these mice would have become moribund by day 36 at the latest. In contrast, vaccination with the hN'-neu-Foxo3 shRNA or the hN'-neu-scramble shRNA DNA vaccines effectively inhibited tumor growth, and, importantly, the hN'-neu-Foxo3 shRNA was much more effective than the hN'-neu-scramble shRNA in prolonging the survival of the mice through day 70, at which time the experiment was terminated (Figure 5a ). It is also noteworthy that a significantly smaller tumor mass was observed in the surviving mice in the hN'-neu-Foxo3 shRNA-vaccinated group than that in mice vaccinated with the hN'-neu-scramble shRNA (Figure 5b ). Taken together, these results provide proof-of-concept evidence to illustrate that the silencing of Foxo3 promotes the therapeutic antitumor efficacy of the hN'-neu DNA vaccine.
Silencing of Foxo3 enhances HER-2/neu DNA vaccine-induced cellular immune responses
Having established that Foxo3 suppression promoted the potency of the hN'-neu DNA cancer vaccine, we next intended to elucidate the underlying mechanisms. We started by probing the humoral and cellular immune responses induced by the hN'-neu-DNA-Foxo3 shRNA vaccine. First, we examined the potential antibody responses to the recombinant extracellular domain of the HER-2/neu protein in mice serum. As shown in Figure 6a , HER-2/neu-specific anti-IgG was detected in mice that received either the hN'-neu-Foxo3 shRNA or the hN'-neu-scramble shRNA; however, it is noteworthy that only a minor increase in the level of HER-2/neu-specific antibody was observed and that the difference in the level of HER-2/neu-specific antibody was not significant between mice vaccinated with the hN'-neu-Foxo3 shRNA and those vaccinated with the hN'-neu-scramble shRNA ( Figure 6a ). We further explored whether ablation of Foxo3-mediated immunosuppression enhances the hN'-neu DNA vaccine-induced cellular immunological responses and the consequent antitumor immunity. To test this possibility, C3H/HeN mice were vaccinated with the shRNAs or the two bicistronic HER-2/neu DNA vaccines. Three days after the last vaccination, lymph node cells were isolated from the vaccinated mice and were subjected to analyses for HER-2/neuspecific cytotoxic responses to MBT-2 cells. We also measured the level of functional HER-2/neu-specific CD8 + T cells, which was determined by their production of intracellular IFN-g. When evaluating the response to the predicted H-2K k -restricted HER-2/neu immunodominant peptide or the recombinant extracellular domain HER-2/neu protein, we found that the lymphocytes from mice vaccinated with the hN'-neu-Foxo3 shRNA or the hN'-neu-scramble shRNA showed higher levels of functional CD8 + T cells (Figures 6b and c) as well as higher HER-2/neu-specific CTL responses ( Figure 6d ) than mice treated with Foxo3 shRNA or scrambled shRNA alone. Importantly, both the level of CTL activity and the number of functional CD8 + T cells were significantly higher in hN'-neu-Foxo3 shRNA-vaccinated mice than those in mice treated with the hN'-neu-scramble shRNA control. Altogether, these results suggest that the upregulation of cellular immune responses was primarily the result of the Foxo3 suppression caused by the hN'-neu DNA vaccine.
Given that Foxo3 suppression in DCs facilitated the survival and resistance of DCs to CD8 + T-cell-induced apoptosis (Figures 4), we next determined whether Foxo3 suppression affected the kinetics of CD8 + T-cell expansion and contraction in response to the HER-2/neu peptide. We measured the level of CD8 + T cells that secreted IFN-g in the lymph nodes of vaccinated mice on various days after immunization. Lymph nodes from naïve C3/HeN mice without tumor inoculation served as the control. Figure 6e shows the level of HER-2/ neu-specific IFN-g-producing CD8 + T cells in the HER-2/neu-immunized mice. In particular, the detected level started to increase on day 1 and reached a maximum on day 3. Subsequently, the number of CD8 + T cells began to decline between day 7 and 21, indicating a contraction phase, and only 0.1% of the CD8 + T cells remained on day 42. Intriguingly, a similar kinetics profile for CD8 + T-cell expansion and contraction was observed in mice vaccinated with the HER-2/neuFoxo3 shRNA. However, HER-2/neu-Foxo3 shRNA-vaccinated mice showed a significantly higher increase in the number of IFN-gproducing CD8 + T cells responding to the HER-2/neu peptide compared with the scrambled shRNA-vaccinated control mice at all sampling time points from day 1 to 42 ( Figure 6e ). Taken together, these results suggest that the increases in both the T-cell expansion and contraction phases likely accounted for the enhancement of the HER-2/neu-specific T-cell responses and consequently the long-term protection against tumors after vaccination with the hN'-neu-Foxo3 shRNA DNA vaccine. The bar graph represents the mean±s.e.m. with six mice per group pooled from two independent experiments. There was no significant difference among group 1, 2 and 4. Similarly, no significant difference was observed between group 1 and 3. Importantly, the level in group 3 is significantly lower than that in the group 2 and 4 (**Po0.01; *Po0.05). (d) The bar graph depicts the percentage of Annexin V-positive apoptotic cells in CD11c + GFP + cells isolated from the inguinal lymph nodes of various DNA-vaccinated mice. The bar graphs are presented as the mean±s.e.m. pooled from two independent experiments (n¼6-8 mice per group). There were no significant difference among group1, 2 and 4. Similarly, no significant difference was found between group 1 and 3. *The level in group 3 is significantly higher than that in the group 2 and 4 (Po0.05), respectively.
Enhancement of HER-2/neu-specific cellular immune responses by Foxo3 suppression is partially because of IL-6 production IL-6 produced by activated DCs leads to the activation of effector T cells. 25, 26 Given that Foxo3 deficiency in DCs was found to cause higher production of IL-6, 17 we therefore evaluated the influence of Foxo3 suppression on IL-6 mRNA expression in DCs. To address this question, we co-administrated the shRNA or hN'-neu DNA vaccines with a plasmid-expressing GFP. Then, 72 h after DNA plasmid administration, CD11c + GFP + double-positive cells were isolated from the inguinal lymph nodes for subsequent analysis of the mRNA levels of IL-6 using quantitative real-time reverse transcription-PCR. Although the Foxo3 shRNA alone had a limited effect on IL-6 expression, the hN'-neu-Foxo3 shRNA significantly increased IL-6 expression relative to that by cells from the hN'-neu-scramble shRNA control mice 72 h after immunization. In addition, CTLA-4 has been proposed to act through the B7 molecules on DCs to initiate the immunosuppressive pathway by active Foxo3 to constrain IL-6 production. 17 It is known that CTLA-4 is expressed on T-regulatory cells (Tregs) and is essential for their function, including the regulation of T-cell response to DNA immunization. For that reason, we decided that it would be interesting to elucidate the role of Tregs in regulating IL-6 expression in DCs from mice treated with the HER-2/neu DNA vaccine. Logically, if Tregs are important for controlling DCs to produce IL-6, depletion of Tregs should allow the HER-2/neu DNA vaccine to increase IL-6 expression and enhance T-cell survival with or without the silencing of Foxo3. To examine this question, we did an in vivo CD25 depletion experiment using an antibody specific for CD25 + Tregs. Surprisingly, we found that the depletion of CD4 + CD25 + T cells had a limited effect on IL-6 expression in DCs from mice vaccinated with the hN'-neu-scramble shRNA or the hN'-neu-Foxo3 shRNA (Supplementary Figure 1) .
We further determined whether the increased IL-6 expression was responsible for the greater activation of HER-2/neu-specific CD8+ T cells. Mice were intraperitoneally injected with a control antibody or an anti-mouse IL-6 receptor antibody (MR16-1) 2 h before DNA vaccination. The CTL activity was evaluated on day 3 and 21 after DNA vaccination. On day 3, the blockade of IL-6-mediated signaling significantly decreased the level of CTL activity in mice vaccinated with the hN'-neu-Foxo3 shRNA; however, on day 21, there was no statistically significant difference in the T-cell responses in mice given the hN'-neu-Foxo3 shRNA with or without co-treatment with the anti-IL-6R antibody (Figure 7b) . Finally, to examine whether IL-6 was required for the enhanced antitumor effect of the hN'-neu-Foxo3 shRNA, the survival time of MBT-2 tumor-bearing mice inoculated with the hN'-neu-Foxo3 shRNA was investigated. As shown in Figure 7c , inhibition of the IL-6 signal only partially decreased the antitumor efficacy of hN'-neu-Foxo3 shRNA, as indicated by the result of a Kaplan-Meier analysis of survival rate (P¼0.48). Additionally, it is noteworthy that the hN'-neu-Foxo3 shRNA co-administered with MR16-1 still resulted in a better survival rate than the scrambled shRNA control did (Po0.05). Overall, these results suggest that the silencing of Foxo3 enhanced the HER-2/neu-specific cell-mediated immune responses in the early T-cell response phase, which is in part a result of IL-6 production induced by the hN'-neu-Foxo3 shRNA vaccination; however, we did not observe a direct correlation between IL-6 expression and the antitumor effect of the HER-2/neu-Foxo3 shRNA DNA vaccine.
The antitumor effect of the hN'-neu Foxo3 shRNA DNA vaccine requires CD8 + T cells We found that Foxo3 shRNA enhanced the hN'-neu DNA vaccineinduced CD8 + T-cell response, so we next investigated the roles of CD8 + T-cell subsets in the antitumor effect of the hN'-neu-Foxo3 shRNA vaccine. The populations of CD8 + T cells from C3/HeN mice were selectively diminished by the anti-CD8 depleting antibody 2.43 (500 mg). As shown in Figure 8 , the therapeutic efficacy of the hN'-neu-Foxo3 shRNA was nearly abolished in mice whose CD8 + T cells had been depleted. CD4 + T cells are required for most T-cell responses, and several lines of evidence have indicated that CD4 + T helper type 1 (Th1) cells are critical for the activation of antigenspecific cytotoxic CD8 + T cells. Thus, the role of the CD4 + T-cell subset in the antitumor effect of the hN'-neu-Foxo3 shRNA vaccine was also examined. The population of CD4 + T cells from C3/HeN mice was selectively diminished by the anti-CD4 depleting antibody GK 1.5 (500 mg). In contrast to CD8 + T cells, CD4 + lymphocytes were found to have a limited role in the overall antitumor effect of the hN'-neu-Foxo3 shRNA, as revealed by the comparable survival rates in 3 , or the poor condition of the mice (that is, the mice were expected shortly to become moribund). Subsequently, the mean tumor volume was calculated for the remaining mice. Experiments were repeated two times with similar results.
mice with or without CD4 + T-cell depletion. Overall, these results clearly indicate that functional CD8 + T cells are primarily responsible for the therapeutic antitumor effect conferred by the hN'-neu-Foxo3 shRNA DNA vaccine, whereas the role of CD4 + lymphocytes is more complex.
Silencing of Foxo3 improves the anti-metastatic efficacy of the HER-2/neu DNA vaccine It is well established that the malignant behavior of tumor cells is affected by the organs in which the tumor cells grow. 27 ,28 Accordingly, we explored whether silencing of Foxo3 enhances the therapeutic effect of the HER-2/neu DNA vaccine on the growth and lung metastasis of MBT-2 tumors. C3/HeN mice were intravenously injected with MBT-2 cells and were vaccinated with shRNAs or the two dual-function HER-2/neu DNA vaccines. On day 31, mice were killed, and their lungs were excised and weighed. As shown in Figure 9 , mice vaccinated with either the hN'-neu-Foxo3 shRNA or the hN'-neu-scramble shRNA exhibited a significantly lower average lung weight than those mice vaccinated with Foxo3 shRNA or scrambled shRNA. In particular, the inhibitory effect of the The number of IFN-g-producing HER-2/neu-specific CD8 + T cells in the inguinal lymph nodes was determined using flow cytometry in the presence of pooled predicted immunodominant HER-2/neu peptides. Analyses were gated on CD3 + cells. Numbers represent the percentage of CD8 + T cells positive for IFN-g. The dot plot shows data from one representative mouse of each group. (c) The bar graph represents the mean ± s.e.m. for six mice per group pooled from two independent experiments. (d) CTLs were generated from lymph node cells as described in Materials and methods section. CTLs were assayed for cytotoxicity at the indicated E:T ratio (25:1) in a standard 12-h CTL assay using MBT-2-luciferase cells as targets. The data are presented as the mean±s.e.m. for three mice per group from a single experiment. NS P40.05; *Po0.05; **Po0.01. The experiments were repeated two times, and similar results were obtained. (e) Kinetics of the HER-2/neu-specific CD8 + T-cell response. The HER-2/neu-specific CD8 + T cells were analyzed on the indicated days after the last immunization by immunodominant HER-2/neu peptide restimulation and intracellular IFN-g staining. Data are representative of two independent experiments with at least three mice per group for each time point. *A statistically significant difference when compared with the untreated naïve mice. **A statistically significant difference when compared with the mice that were given the hN'-neu-scramble shRNA vaccine.
hN'-neu-Foxo3 shRNA vaccine on lung metastasis was more potent than that of the scrambled control vaccine (Po0.05). This result highlights the role of Foxo3 suppression in the ability of the HER-2/ neu DNA vaccine to limit tumor cell growth in mice-bearing MBT-2 tumors capable of lung metastasis.
DISCUSSION
In this report, we exploited the immunosuppressive effect of Foxo3 to modulate the antitumor immune responses elicited by the HER-2/ neu DNA vaccine. Our results showed that hN'-neu-Foxo3 shRNA vaccination not only inhibited the growth of p185neu-expressing MBT-2 tumors but also prolonged the survival of tumor-bearing mice compared with mice vaccinated with either the hN'-neu-scramble shRNA vaccine or Foxo3 shRNA alone. Moreover, we showed that the increase in the antitumor efficacy of the HER-2/neu DNA vaccine caused by the silencing of Foxo3 correlated with the enhancement of CD8 + CTL responses induced by HER-2/neu vaccination. Finally, the Foxo3 shRNA-induced enhancement of the anti-metastatic effect of the HER-2/neu DNA vaccine was also clearly revealed.
One possible mechanism by which Foxo3 suppression enhances DC-mediated T-cell responses may be the ability of Foxo3 suppression to promote the survival of DCs (Figure 4) . It is well known that the activation-induced apoptosis of DCs causes a decrease in the interaction between APCs and lymphocytes, leading to the downregulation of the molecules with anti-apoptotic functions and a potential upregulation of pro-apoptotic molecules in T cells. 29 This process naturally leads to a decline in the numbers of activated antigen-specific CD8 + T cells and as a result compromises the potency of DNA vaccines. To overcome this problem inherent to DNA vaccines, several groups have developed strategies to prolong the survival of DCs in vivo by co-administering DNA encoding anti-apoptotic proteins or shRNAs targeting key pro-apoptotic proteins, culminating in the enhancement of DNA vaccine potency. 5, 29, 30 Foxo3 is implicated in apoptosis induction, and, importantly, deficiency in Foxo3 leads to impaired apoptosis in vitro and in vivo. [13] [14] [15] 31 Consistent with the pro-apoptotic role of Foxo3, in this study, we observed that the silencing of Foxo3 led to an increase in the number of APCs and to a reduction in the percentage of DCs undergoing apoptosis in mice vaccinated with the Figure 7 The effect of IL-6 produced during the HER-2/neu-specific T-cell responses and the therapeutic effect of the hN'-neu-Foxo3 shRNA DNA vaccine. (a) GFP-expressing CD11c + cells were isolated from the inguinal lymph nodes 72 h after the last DNA vaccination. The IL-6 mRNA level was measured by quantitative real-time reverse transcription (RT)-PCR. The data were normalized to GAPDH expression in each sample, and the relative expression levels are expressed as the fold increase compared with the untreated control group. The bar graphs are presented as the mean±s.e.m. pooled from two independent experiments (n¼12 mice per group). NS P40.05; *Po0.05. (b) CTLs were generated from lymph node cells as described in Materials and methods section. CTLs were assayed for cytotoxicity at the indicated E:T ratio (25:1) in a standard 12-h CTL assay using MBT-2-luciferase cells as targets. The data are presented as the mean±s.e.m. for three mice per group from a single experiment. NS P40.05; *Po0.05 (c) The lifespan of the C3/HeN mice after challenge with MBT-2 tumor cells. *A statistically significant difference when compared with the untreated shRNA group (Po0.05). **A statistically significant difference when compared with the mice that were given the hN'-neu-scramble shRNA vaccine (Po0.05) and the untreated mice (Po0.01). # A statistically significant difference between the hN'-neu-Foxo3 shRNA + MR16-1 group and the hN'-neu-scramble shRNA + MR16-1 group (Po0.05). All experiments were repeated two times, and similar results were obtained.
hN'-neu-Foxo3 shRNA DNA (Figure 4d) . Accordingly, it is reasonable to speculate that the increased number of APCs would in turn sustain T-cell survival and consequently enhance T-cell-mediated immune responses. Furthermore, although the mechanism by which the silencing of Foxo3 promotes DC survival is unknown, our results argue that the prolonged survival of DCs could be, at least in part, the result of the resistance of DCs to apoptosis induced by CD8+ T cells.
In line with previous observations by Dejean et al., 17 we also observed that the Foxo3 shRNA-enhanced HER-2/neu antigen-specific T-cell function correlated with increased IL-6 production by CD11c + DCs. This was supported by our finding that the blockage of IL-6 receptor-mediated signaling led to a decrease in HER-2/neu-specific T-cell activity (Figure 6b ) in HER-2/neu-Foxo3 shRNA-vaccinated mice. IL-6 has long been regarded as a proinflammatory cytokine, and it also exerts strong pro-survival effects on activated antigen-specific T cells. 25, 26 Thus, it is plausible to reason that the promoting effect of Foxo3 suppression on HER-2/neu antigen-specific CTL activity is in part attributed to the increase in T-cell survival through the enhanced IL-6 production of Foxo3-deficient DCs.
CD4 + T cells are required for most T-cell responses. In particular, CD4 + Th1 cells are critical for the activation of antigen-specific cytotoxic CD8 + T cells. 32 Our previous study demonstrated that gene gun administration of the naked hN'-neu DNA vaccine predominantly induced a Th1 response, suggesting that CD4 + Th1 cells may be responsible for the antitumor immunity elicited by the gene gun-delivered naked DNA vaccine. 33 However, this study showed that the depletion of CD4 + T cells had a limited effect on the antitumor effects of the hN'-neu-Foxo3 shRNA vaccine (Figure 8 ). Therefore, we propose three possible reasons to explain this unexpected result. First, although 495% of CD4 + T cells was depleted by our experimental protocol, we cannot exclude the possibility that the residual 2-5% of the CD4 + T cells were sufficient to contribute to further immune activation. Second, the induction of specific cytotoxic CD8 + T-cell responses by gene gun-delivered DNA vaccines is likely to be achieved by CD4 + Th1 cell-dependent and CD4 + Th1 cell-independent pathways. Third, the MBT-2 tumor implantation may induce negative regulatory CD4 + T cells, including CD4 + CD25hi T cells, 31 IL-10-producing CD4 + T-regulatory type 1 (Tr1) cells 34 or transforming growth factor-b-producing CD4 + (Th3) regulatory cells, 35 thereby partially suppressing the effects of specific CD8 + CTLs. Previous reports have shown that the depletion of CD4 + T cells dramatically induces the penetration of CD8 + T cells into the tumor sites of a B16 melanoma model. 36 We have also shown that the combination of CD4 + T-cell depletion and intramuscular injection of the hN'-neu DNA vaccine causes dramatic increases in CD8 + T-cell responses and antitumor effects in a MBT-2 tumor model. 22 We propose that both CD8 + T cells and conventional CD4 + T-helper cells may contribute to the antitumor immunity against HER-2/neu-expressing tumors effected by the HER-2/neu DNA vaccine delivered by a gene gun. Moreover, this notion suggests that the removal of CD4 + Treg lymphocytes may further increase the effectiveness of hN'-neu DNA vaccination.
Our previous and current studies all indicate that noncarrier naked DNA vaccines delivered via gene gun administration induce strong and lasting CD8 + T cell-mediated immune responses, but these vaccines rather induce a lower level of antibody responses than that induced by DNA-coated gold particles delivered by gene gun. 37, 38 However, it is well established that the anti-p185 antibody has an important role in directly inhibiting the growth of HER-2-positive tumors in vitro and in several preclinical models. 33, 39 Furthermore, it has also been documented that the collaboration of both the HER-2/neu antibody and T cells contributes to the rejection of HER-2/neu tumors in transgenic mice and the eradication of clinically evident p185neu-positive tumors in wild-type BALB/ mice. 23, 40, 41 Given the importance of antibodies in anti-HER-2/neu immunity, potent immunotherapy regimens against HER-2/neu-positive tumors may be designed by combining hN'-neu-shFoxo3 DNA vaccination with passive immunization with anti-p185neu antibodies. Furthermore, other strategies that can elicit both strong antibody and T-cell immune responses to the HER-2/neu antigen, such as the addition of mLAG-3Ig 42 or a TLR-9 43 agonist in the DNA vaccination or the fusion of the extracellular domain of the CTLA-4 to the HER-2/neu, 44 may confer synergistic antitumor effects against HER-2/neu-positive tumors and could be attractive regimens for translation to a clinical setting. In summary, for the first time, we present evidence demonstrating that the silencing of Foxo3 in DCs in vivo by the HER-2/neu DNA vaccine represents an innovative and effective approach to enhance the HER-2/neu antigen-specific CD8 + T-cell immune responses and therapeutic antitumor effects. We further propose that our results are encouraging for the application of this strategy to enhance DNA vaccine potency for the control other cancers with known antigens.
MATERIALS AND METHODS
Mice and cell lines
Inbred female C57BL/6 and C3/HeN mice, 6-8 weeks of age, were obtained from the Laboratory Animal Center at National Cheng Kung University (Tainan, Taiwan). OT-I T-cell antigen receptor transgenic mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were maintained under specific pathogen-free conditions, and all study protocols were approved by the Animal Welfare Committee at National Cheng Kung University. The murine bladder tumor cell line MBT-2 was originally obtained from transplantable N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors in C3H mice and is known to be histologically similar to human bladder cancer. 45 We further observed the surface expression of p185neu and major histocompatibility complex class I molecules on MBT-2 cells using flow cytometry. 22 Plasmid construction and preparation of the DNA vaccine A shRNA was constructed within a pHsU6 vector as described previously. 46 The targets were 5¢-GCAGCCGTGCCTTGTCAAA-3¢ÿ (for mouse Foxo3 shRNA) and 5¢-GCCGACCCGGTGTACTATA-3¢ÿ (for scramble shRNA). Full-length mouse FOXO3 genes were cloned from C3/HeN mouse liver and subcloned into a pcDNA3.1/myc-His-B(+) vector (Invitrogen, Carlsbad, CA, USA). The resulting plasmids were named mFoxo3. The hN'-neu-Foxo3 shRNA and hN'-neu-scramble-shRNA plasmids were constructed by subcloning the U6 promoter/Foxo3 shRNA, the U6 promoter/scramble shRNA PCR product from pHsU6-mouse Foxo3 shRNA or the pHS-U6-scramble shRNA into the hN'-neu DNA vaccine containing the extracellular domain of human neu driven by the cytomegalovirus promoter. The schematic representation of expression vectors are shown in Figure 1 . The Endofree Qiagen Plasmid Mega Kit System (Qiagen, Hilden, Germany) was used for the large-scale purification of plasmid DNA. The purified plasmid DNA used in the study was suspended in sterile water at the final concentration of 1 mg ml -1 .
Western blotting Preparation of BMDCs
BMDCs were generated from C57BL/6 mouse bone marrow as previously described. 47 In brief, all mice were killed by cervical vertebrate dislocation. Femurs and tibias were obtained from the mice. After removing all muscle tissue from the femurs and tibias with gauze, the bones were placed in a 10-mm dish with 70% alcohol for 1 min, washed twice with phosphate-buffered saline, and transferred into a fresh dish with RPMI 1640. Both ends of the bones were cut with scissors in the dish, and the marrow was flushed out using 5-10 ml of RPMI 1640 with a syringe and a 25-gauge needle. The tissue was suspended and passed through a nylon mesh to remove small pieces of bone and debris. Then red cells were lysed with red blood cell lysis buffer. The cells were washed with phosphate-buffered saline and then resuspended in medium. We placed 7-10Â10 5 cells in 24-well plates in 1 ml of medium supplemented with 10 ng ml -1 recombinant murine granulocyte-macrophage colony stimulating factor (rmGM-CSF). Cells were incubated at 37 1C in a 5% CO 2 humidified atmosphere. The cultures were usually fed every 2 days, and nonadherent cells were harvested on day 7. CD11c + DCs were further positively selected with CD11c (N418) microbeads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions, and these cells were used for experiments. The purity of the CD11c + cells was 490% (data not shown). Determination of the number of apoptotic cells DNA-transfected BMDCs were pulsed with 1-mg OVA 257À264 (OVAP 1 ) and subsequently incubated with OT-I T cells at different E:T ratios (25:1, 10:1 or 1:1). After 24-h incubation, the cells were harvested and positively selected with CD11c (N418) microbeads (Miltenyi Biotec). Apoptotic cell death in the enriched CD11c + cell population was measured by flow cytometry using a phycoerythrin-conjugated Annexin V detection kit-I (BioVision, Palo Alto, CA, USA) as per the manufacturer's protocol. Flow cytometric analysis was performed using a FACSCalibur, and the data were analyzed using CELLQuest software (BD Bioscience) by gating on 2Â10 4 cells per sample.
DCs induced OT-I CD8 + T-cell differentiation
Detection of enhanced GFP-positive DCs in the inguinal lymph nodes
This protocol was modified from that published in a previous report. 5 In brief, C3H/HeN mice (six per group) were first primed with the hN'-neu DNA vaccine via gene gun administration. After 7 days, the mice received 5 mg of pEGFP-N1 DNA plasmid (Clontech Laboratories, Inc., Mountain View, CA, USA) with scrambled shRNA, Foxo3 shRNA, hN'-neu-Foxo3 shRNA or hN'-neu-scramble shRNA. Pooled right and left inguinal lymph nodes were collected 72 h after DNA plasmid administration. The mice were inoculated with shRNA or the hN'-neu DNA vaccine without the pEGFP-N1 DNA plasmid as a negative control. The CD11c-positive cells were enriched from a single cell suspension of isolated lymph nodes using CD11c + microbeads (Miltenyi Biotec). The enriched CD11c + population was identified by forward and side scatter and gated around a population of cells with the size and granular characteristics of DCs. FACSCalibur flow cytometry was used to determine the percentage of GFP-positive CD11c + DCs in the gated population. To detect the percentage of apoptotic CD11c + GFP + cells, enriched CD11c + cells were prepared and measured by flow cytometry using a phycoerythrinconjugated Annexin V detection kit-I according to the manufacturer's protocol. Flow cytometric analysis was performed on a FACSCalibur using CELLQuest software; 1Â10 4 cells per sample were analyzed.
Therapeutic efficacy of the DNA vaccine on tumor growth
The in vivo tumor treatment experiments were performed as described previously. 22 In brief, female C3/HeN mice were challenged by subcutaneous injection in the flank with 1Â10 6 MBT-2 cells in 0.5 ml of cold phosphatebuffered saline. On day 10 when tumors were palpable, mice received 10 mg of scrambled shRNA, Foxo3 shRNA, hN'-neu-scramble shRNA or hN'-neu-Foxo3 shRNA DNA plasmid dissolved in 20 ml of autoclaved double-distilled water; each of these solutions was directly added to the loading hole near the nozzle and then delivered to the shaved abdominal region of the mice at a discharge pressure of 60 p.s.i. using a low-pressure-accelerated gene gun (Bioware Technologies Co. Ltd, Taipei, Taiwan) three times at weekly intervals. Tumor sizes in the mice were recorded two or three times per week. Mice were killed and the date of death recorded when the mean diameter of the tumor reached 2500 mm 3 or when the mice were in a poor condition and expected shortly to become moribund. Significant differences in mouse survival were evaluated by Kaplan-Meier analyses of the survival rates (GraphPad Software, San Diego, CA, USA).
Cytotoxicity assay
Three days after the last DNA vaccination, pooled right and left inguinal lymph node cells from immunized mice were cultured in RPMI 1640 containing 10% fetal calf serum, 50 mM 2-mercaptoethanol and 10 mg ml -1 recombinant HER-2/ neu protein (R&D Systems, Minneapolis, MN, USA) for 5 days. After in vitro stimulation, the lymph node cells were co-cultured with 1Â10 4 MBT-2 luciferase cells at an E:T ratio of 25:1 in 96-well culture plates. After 12-h incubation, 100 ml of supernatant was harvested from each well, and the released luciferase activity was assayed with luciferin using a Modulus Single Tube Multimode Reader (Turner Bio Systems, Sunnyvale, CA, USA). To analyze the involvement of IL-6 signaling in the cytotoxicity activity of cells from draining inguinal lymph nodes in response to DNA vaccine administration, 2 mg of an anti-mouse IL-6 receptor antibody (MR16-1, a generous gift from Dr Osugi and Dr Mihara, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan) was intraperitoneally administered to the mice 2 h before DNA vaccination at weekly intervals until the end of the experiment. The specificity and blocking ability of this monoclonal antibody has been confirmed in previous reports. 48, 49 Detection of antigen-specific CD8 + /IFN-c + T lymphocytes in lymph nodes Three days after the last DNA vaccination, pooled right and left inguinal lymph node cells were harvested from various DNA-transfected mice. Before intracellular IFN-g staining, 1Â10 6 pooled lymph node cells were incubated for 18 h with a peptide pool composed of 10 mg ml -1 each of peptide 362-370 (EFAGK-KI) (BioBasic, Canada) and peptide 404-412 (EEITGYLYI) (BioBasic, Markham, Canada) of the HER-2/neu sequence. These short peptides (nonamers) are predicted to bind the H-2K k glycoproteins with high affinity, and we selected peptides with the two top-scoring sequences identified by a prediction algorithm (Immune Epitope Database and Analysis Resource, 50 SYFPEITHI database). 51, 52 Brefeldin A (10 mg ml -1 ) (Sigma-Aldrich, St Louis, MO, USA) was added during the last 4.5 h of culturing. The cells were surface-stained with allophycocyanin (APC)-conjugated CD3 (clone 17A2) (eBioscience, San Diego, CA, USA) and phycoerythrin-conjugated anti-CD8 (clone 53-6.7) (eBioscience). Subsequently, the cells were fixed/permeabilized (Cytofix/Cytoperm Plus; BD Biosciences) and stained with FITC-conjugated anti-IFN-g (clone XMG1.2) (eBioscience). The gating strategy used to analyze IFN-g co-expression in CD8 + cells was as follows: lymphocytes were gated on low forward and side scatter lymph node cells (FSC/SSC), and subsequently, the CD3 + cells were further gated within the lymphocyte gate. Cells fulfilling both criteria were acquired (2Â10 5 events), and we measured the proportion of the CD8 + IFN-g + double-positive cells using a FACSCalibur flow cytometer.
Depletion of T-cell subsets in vivo
Mice were depleted of CD4 + and CD8 + T cells as described. 22 . Briefly, mice received intraperitoneal treatment of rat anti-mouse mAb (clone 2.43, 0.5 mg per /mouse per week for CD8; GK 1.5, 0.5 mg per mouse per week for CD4; or PC61, 0.5 mg per mouse per week for CD25). A purified rat IgG was used as the control antibody. The first injection occurred 2 days before DNA vaccination, and injections continued at weekly intervals until the end of the experiment. Depletion was verified by FACScan analysis of peripheral blood cells, which revealed 495% depletion.
Evaluation of therapeutic efficacy in a mouse model of lung metastatic MBT-2 tumors
Mice were challenged with 5Â10 5 MBT-2 tumor cells in 0.5 ml of phosphatebuffered saline per mouse through the tail vein. After 5 days, mice were injected via gene gun administration three times at weekly intervals with 10 mg of the indicated expression vector. The effect of these treatments on the growth and lung metastasis of MBT-2 tumors were then evaluated.
Statistical analysis
All statistical analyses were performed with the GraphPad Prism software package version 4.0. Additionally, the relative expression levels of Foxo3, HER-2/neu and IL-6 mRNA. Additionally, data of the Ag-specific T-cell responses, percentage of GFP + cells among the gated CD11c + cells, Annexin V staining assays, specific cytotoxicity and intracellular cytokine staining with flow cytometry analysis were evaluated by analysis of variance test between groups followed by Tukey's test to determine the significance of differences between pairs of groups. Furthermore, Kaplan-Meier method was used for analyzing the survival rate of mice, wherein statistical significance was determined by log-rank analysis.
